

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7061807

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LIFE SCIENCES RESEARCH PARTNERS	06/10/2021
KATHOLIEKE UNIVERSITEIT LEUVEN	07/10/2021
RECEIVING PARTY DATA	
Name:	IMCYSE SA
Street Address:	AVENUE PRÉ-AILY 14
City:	LIÈGE
State/Country:	BELGIUM
Postal Code:	4031
PROPERTY NUMBERS Total: 14	
Property Type	Number
Patent Number:	9249202
Patent Number:	10662232
Application Number:	16848086
Patent Number:	9248171
Application Number:	16804288
Application Number:	16726411
Patent Number:	8999346
Patent Number:	10617748
Patent Number:	9044507
Patent Number:	9861661
Patent Number:	10982196
Patent Number:	9394517
Patent Number:	10899795
Application Number:	17130192
CORRESPONDENCE DATA	
Fax Number:	(703)816-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7038164000

Email: mgaszner@nixonvan.com, anorris@nixonvan.com
Correspondent Name: NIXON & VANDERHYE, PC
Address Line 1: 901 N. GLEBE ROAD
Address Line 2: SUITE 1100
Address Line 4: ARLINGTON, VIRGINIA 22203

ATTORNEY DOCKET NUMBER: 2752

NAME OF SUBMITTER: MIKLOS GASZNER

SIGNATURE: /Miklos Gaszner, Reg. No. 61,314/

DATE SIGNED: 12/08/2021

Total Attachments: 5

source=LSRP KUL TO IMCYSE SA#page1.tif

source=LSRP KUL TO IMCYSE SA#page2.tif

source=LSRP KUL TO IMCYSE SA#page3.tif

source=LSRP KUL TO IMCYSE SA#page4.tif

source=LSRP KUL TO IMCYSE SA#page5.tif

IP ASSIGNMENT AGREEMENT

BETWEEN

- (1) **Life Sciences Research Partners**, a non-profit organisation organised under the laws of Belgium, having its registered office at Herestraat 49, 3000 Leuven, registered with the Crossroads Bank for Enterprises under number 0435.768.243 (RLE Leuven)

Hereinafter referred to as “LSRP”;

- (2) **Katholieke Universiteit Leuven**, having its registered office at Oude Markt 13, 3000 Leuven, registered with the Crossroads Bank for Enterprises under 0419.052.173 (RLE Leuven), hereby duly represented by KU Leuven Research & Development, having its offices at Waaistraat 6 box 5105, 3000 Leuven

Hereinafter referred to as “KUL”

LSRP and KUL are hereinafter referred to jointly as the “Assignor”

And

- (3) **Imcyse SA**, a company organised under the laws of Belgium, having its registered office at Avenue Pré-Aily 14, 4031 Liège, registered with the Crossroads Bank for Enterprises under number 0828.385.542 (RLE Liège, subsection Liège)

Hereinafter referred to as “ImCyse” or the “Assignee”

WHEREAS

- a) The Assignor is the owner of patent rights on the patent registrations and applications listed in Annex I (the “Patents”).
- b) The Assignor has decided to transfer the Patents in full to the Assignee.
- c) The Assignee is willing to acquire the Patents.

THE PARTIES HAVE AGREED AS FOLLOWS

1. The Assignor hereby assigns to the Assignee, which accepts, full title in the Patents.
2. This assignment shall be notified and registered at the competent Patent Offices by the Assignee. The costs involved in recording the assignment will be borne by Assignee.

Drawn up in three (3) original counterparts, each Party declaring receipt of one (1).

On behalf of LSRP, ASSIGNOR

DocuSigned by:



B16C125FF7594D2...
(Signature)

Name: Desire Jose Louis Collen

Title: Representative of Chairman

Date: 06/10/2021

On behalf of ImCyse, ASSIGNEE

DocuSigned by:



7607A3752FF34BF...
(Signature)

Name: Denis Bedoret

Title: CEO

Date: 06/10/2021

On behalf of KUL, ASSIGNOR

DocuSigned by:



636258A95A4F42D...
(Signature)

Name: Paul Van Dun

Title: General Manager

Date: 07/10/2021

Name: Koenraad Debackere

Title: Managing Director

Date: 06/10/2021

DocuSigned by:



ED5BBD7E7CE34D3...

Annex 1 - List of assigned patents

1) Internal reference	LSRP035 - IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS	
Filing Date-PCT#	13/08/07 - PCT/EP2007/007165 (WO2008017517)	
Coverage	Country	Application number
	AU	2007283731
	CA	2660605
	EP	07801643, validated in AT (AT E 816927), DK, DE (DE 60 2007 047 285.7), GR (3090424), FI, FR, GB, IE, BE, LU, PT, NL, PL, SE, CH, LI, ES (ES 2601432 T3), TR (TR 2016 15523 T4) and IT (502016000110088).
	EP-div1	11187012, validated in AT (AT E 955761), BE, CHL, DE (DE 60 2007 053 501.8), DK, ES (ES 2657504 T3), FI, FR, GB, GR (3095233), IE, IT (502018000007362), LU, NL, PL, PT, SE and TR (TR 2018 00975 T4).
	EP-div2	11187013, validated in AT (AT E 949791), BE, CHL, DE (DE 60 2007 053 249.3), DK, ES (ES 2657480 T3), FI, FR, GB, GR (3095073), IE, IT (502018000005292), LU, NL, PL, PT, SE and TR (TR 2018 00595 T4).
	EP-div3	11187014, validated in BE, CHL, DE (DE 60 2007 057 008.5), ES (ES 2709176 T3), FR, GB, IT (502019000009631), LU and NL.
	JP	2009523209
	US	12/377048
	US-div1	14/976259
	US-div2	16/848086

2) Internal reference	LSRP042 - IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION	
Filing Date-PCT#	14/02/08 - PCT/BE2008/000010 (WO2009100505)	
Coverage	Country	Application number
	AU	2008350785
	CA	2715517
	EP	08706161, validated in BE, CHL, DE (DE 60 2008 049 328.8), ES (ES 2626115 T3), FR, GB, IT (502017000066436), LU and NL.
	US	12/735744
	US-cont	16/804288

3) Internal reference	LSRP043 - STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO ALLOFACTORS	
Filing Date-PCT#	16/02/09 - PCT/EP2009/051806 (WO2009101206)	
Coverage	Country	Application number
	AU	2009214040
	CA	2724440
	EP	09710097, validated in DE (DE 60 2009 038 363.9), FR, GB, BE, NL, CH, LI, ES (ES 2584430 T3), IT (502016000080109), IE, FI, AT (AT E 796304), PL, TR (TR 2016 10457 T4), NO and LU.
	US-cont	16/726411

4) Internal reference	LSRP044 - IMMUNOGENIC CONTROL OF TUMOURS AND TUMOUR CELLS	
Filing Date-PCT#	16/02/09 - PCT/EP2009/051804 (WO2009101205)	
Coverage	Country	Application number
	AU	2009214039
	AU-div	2013270496
	CA	2715488
	EP	09710780, validated in BE, CHL, DE (DE 60 2009 051 835.6), ES (ES 2676630 T3) , FR, GB, IT (502018000020589), LU and NL.
	EP-div1	13150813, validated in BE, CHL, DE (DE 60 2009 045 024.7), ES (ES 2627882 T3), FR, GB, IT (502017000061872), LU and NL.
	HK-div1	14101218
	US	12/735740
US-div	14/589134	

5) Internal reference	LSRP045 - ELIMINATION OF IMMUNE RESPONSES TO VIRAL VECTORS	
Filing Date-PCT#	16/02/09 - PCT/EP2009/051803 (WO2009101204)	
Coverage	Country	Application number
	AU	2009214038
	CA	2715484
	EP	09711066, validated in DE (DE 60 2009 031 739.3), FR, GB, ES (ES 2545885 T3), IT (502015000044974), IE, FI, AT (AT E 731539), NL, PL, TR (TR 2015 11188 T4), BE, NO, CH, LI and LU.
	US	12/735754
	US-div	14/686855

SHORT FORM AGREEMENT

6) Internal reference	LSRP046 - IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS	
Filing Date-PCT#	16/02/09 - PCT/EP2009/051808 (WO2009101208)	
Coverage	Country	Application number
	AU	2009214042
	CA	2715611
	EP	09711135, validated in DE (DE 60 2009 031 740.7), FR, GB, BE, NL, CH, LI, ES (ES 2545886 T3) and IT (502015000044806).
	EP-div	13187209, validated in BE, CHL, DE (DE 60 2009 046 808.1), ES (ES 2637812 T3), FR, GB, IT (502017000100561), LU and NL.
	HK-div	14110064
	US-div	14/450722

7) Internal reference	LSRP047 - CD4+ T-CELLS WITH CYTOLYTIC PROPERTIES	
Filing Date-PCT#	16/02/09 - PCT/EP2009/051807 (WO2009101207)	
Coverage	Country	Application number
	AU-div	2014259586
	CA	2715536
	EP	09711368, validated in BE, CHL, DE (DE 60 2009 048 427.3), ES (ES 2650236 T3), FR, GB, IT (502017000138872), LU and NL.
	US-cont	14/135630

8) Internal reference	LSRP054 - MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES	
Filing Date-PCT#	30/01/13 - PCT/EP2013/000006 (WO2013113076)	
Coverage	Country	Application number
	AU	2013214700
	BR	112014017862
	CA	2863126
	CN	201380007164
	MO	J/003504
	EP-div	19178529
	HK-div	42021024650
	IN	6403/DELNP/2014
	IN-div	202018032121
	JP	2014553584
	JP-div	2017229125
	KR-div	1020207000369
	RU	2014135406
	US	14/375324
	US-div	17/130192
	ZA	2014/05197